Investigating a new intrathecal drug for lung cancer that has spread to the spinal fluid
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new way of giving an experimental drug directly into the fluid around the brain and spinal cord for people whose lung cancer has spread there and stopped responding to targeted therapy. The goal is to see if it can shrink or control the cancer in this area and help with symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer with an EGFR mutation that has been treated with targeted therapy and is no longer responding.
- Cancer cells have been found in the fluid around your brain and spinal cord (leptomeningeal metastasis).
- You feel well enough to carry out daily activities (Eastern Cooperative Oncology Group score of 3 or less).
- Your neurological symptoms have been stable for the past week, with no new or worsening symptoms.
- Your blood counts and liver and kidney function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.
This trial tests a new drug called BioTTT001 for people with non-small cell lung cancer (NSCLC) that has spread to the fluid around the brain or the lining of the brain (leptomeninges). The goal is to see if the drug is safe and can help control the cancer.
This study tests whether giving a higher dose of an EGFR-targeted pill, either alone or with a chemotherapy drug injected into the fluid around the spinal cord, can control lung cancer that has spread to the lining of the brain (called leptomeningeal metastases). It is for people whose cancer has gotten worse in the brain lining while on a standard dose of this type of medication.
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
This trial studies a new drug called sacituzumab tirumotecan combined with brain radiation for people with EGFR-positive lung cancer that has spread to the brain and has grown despite targeted therapy. The goal is to see if this combination can better control the brain tumors.
This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.
Hear when a new EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.